The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of May 26 ... Certain von Hippel-Lindau (VHL) disease-associated tumors WELIREG (belzutifan) is indicated for the ...

drug Welireg (belzutifan) failed to produce statistically significant OS improvement in a type of kidney cancer. It also produced 20-25% ORR. Welireg has a mechanism of action somewhat similar to ...

Rahway, New Jersey Tuesday, January 28, 2025, 10:00 Hrs [IST] ...

Researchers at the University of Basel are able to test in parallel the effects of over 1,500 active substances on cell ...

Researchers are able to test in parallel the effects of over 1500 active substances on cell metabolism. Their analysis also led to the discovery of previously unknown mechanisms for known medications.

The question of putative mechanisms of action continues to haunt psychopharmacology. Put simply, we know these drugs work, but we have very little idea how. We make guesses based on the ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.

Many people wish not only to live as long as possible, but above all to do so without any health restrictions. However, with ...

A Prescription Drug User Fee Act target date of May 26, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug ...

The median progression-free survival was 30.3 months, and the median overall survival was not reached. The combination of belzutifan and cabozantinib has demonstrated “promising” antitumor ...

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...

There’s such an abundance that we can create a list purely of action shows to look forward to in 2025. Whether you’ve already finished season 2 of Squid Game and are hankering for more action ...